Navigation Links
Asmacure Ltee to Present at the 2011 BioPharm America Conference
Date:9/1/2011

QUEBEC CITY, Sept. 1, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will present at the 2011 BioPharm America Conference taking place September 7-9.  Mr. Driscoll will provide an overview of Asmacure's nicotinic acetylcholine receptor technology, with emphasis on the company's lead product in development for the treatment of asthma, ASM-024.  The presentation will be given on Friday, September 9, at 9:00 a.m. EDT in the Hancock room at the Westin Boston Waterfront Hotel in Boston, MA.

About Asmacure Ltee

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases.  The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma.  ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada.  The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec.  For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com  


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
2. Verenium to Present at Upcoming Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
5. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
6. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
7. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
8. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
9. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
11. Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):